Abstract
BackgroundNL-201 is a potent, selective, and long-acting computationally designed alpha-independent agonist of the IL-2 and IL-15 receptors that is being developed as an immunotherapy for cancer. Downregulation of MHC class...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have